FindTrial
Sign In

Clinical Efficacy and Mid- to Long-Term Effects of Tuina Therapy for Knee Osteoarthritis: A Single-Center Randomized Controlled Trial

Evidence-based Optimization, Demonstration and Promotion Research on Traditional Chinese Medicine Rehabilitation Program for Early and Middle-stage Knee Osteoarthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001661
Enrollment
Unknown
Registered
2026-07-06
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Tuina Group:Tuina Therapy
Drug group:Celecoxib orally
Health Education Group:Health Education

Sponsors

Changchun University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for knee osteoarthritis (KOA) according to the 2021 Chinese Medical Association Guidelines for Diagnosis and Treatment of Osteoarthritis and the 2020 Edition of the Chinese Guidelines for TCM Diagnosis and Treatment of Knee Osteoarthritis; Kellgren-Lawrence radiographic grade I–III. 2. Age 40–75 years, regardless of gender. 3. Visual Analog Scale (VAS) pain score =4 points in the affected knee. 4. No treatment for KOA within the past 3 months, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, glucosamine, physical therapy, acupuncture, tuina, or intra-articular injections. 5. Willing to participate voluntarily and able to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Secondary knee osteoarthritis (e.g., post-traumatic, rheumatoid arthritis, gouty arthritis, etc.). 2. History of surgery or severe trauma in the affected knee. 3. Presence of severe primary diseases affecting the heart, liver, kidneys, hematopoietic system, or mental disorders. 4. Allergy to celecoxib or NSAIDs, or history of active peptic ulcer disease or bleeding disorders. 5. Local skin damage, infection, or dermatological conditions in the affected knee. 6. Pregnant or breastfeeding women 7. Patients currently participating in other clinical trials

Design outcomes

Primary

MeasureTime frame
Visual Analog Scale;Western Ontario and McMaster Universities Osteoarthritis Index;—

Secondary

MeasureTime frame
Quadriceps Morphological Assessment;Knee Joint Skin Temperature Assessment;Ligament Stiffness Evaluation;Dynamic and static balance ability;The MOS 36-Item Short-Form Health Survey,SF-36;Disease recurrence status;Medication adherence testing;—

Countries

China

Contacts

Public ContactWang Yufeng

Changchun University of Chinese Medicine

Wangchn@126.com+8615943092035

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026